




>>Entry Name: Omapatrilat, USAN

Synonym(s): Octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, 9Cl. BMS 186716



CAS Registry Number: 167305-00-2

Molecular Formula: C₁₉H₂₄N₂O₄S₂

Molecular Weight: 408.542

Accurate Mass: 408.117748

Percentage Composition: C 55.86%; H 5.92%; N 6.86%; O 15.66%; S 15.70%

Biological Use/Importance: Potent angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitor. May be useful for the treatment of hypertension and congestive heart failure

Development Status: Phase II clinical trials (1997)

>>Variant: (3'S,4S,7S,10aR)-form

Molecular Formula: C₁₉H₂₄N₂O₄S₂

Molecular Weight: 408.542

Accurate Mass: 408.117748

Percentage Composition: C 55.86%; H 5.92%; N 6.86%; O 15.66%; S 15.70%

Physical Description: Solid

Melting Point: Mp 218-220 dec.°

Optical Rotation: [α]_D -78.9 (c, 0.46 in DMF)

References:

- Eur. Pat.*, 1994, *Bristol-Myers Squibb*, 629 627; *CA*, **123**, 198836b, (*synth, pharmacol*)
Jemal, M. *et al.*, *J. Chromatogr., B: Biomed. Appl.*, 1997, **693**, 109-116; **698**, 123-132, (*hplc-ms*)
Robl, J.A. *et al.*, *J. Med. Chem.*, 1997, **40**, 1570-1577, (*synth, pharmacol, pmr, cmr, ir*)
Trippodo, N.C. *et al.*, *Am. J. Hypertens.*, 1998, **11**, 363-372, (*pharmacol*)
Graul, A. *et al.*, *Drugs of the Future*, 1999, **24**, 269-277